Based on the results of this study, we suggest that for BCS class III drug with high < em class= " a-plus-plus " > F < /em > < sub class= " a-plus-plus " > a < /sub > (about & gt;80  %), the biowaiver should extend to rapid dissolution ( < em class= " a-plus-plus " > T < /em > < sub class= " a-plus-plus " > 85  % < /sub >  = 30 min), and 30 %..."> Based on the results of this study, we suggest that for BCS class III drug with high < em class= " a-plus-plus " > F < /em > < sub class= " a-plus-plus " > a < /sub > (about & gt;80  %), the biowaiver should extend to rapid dissolution ( < em class= " a-plus-plus " > T < /em > < sub class= " a-plus-plus " > 85  % < /sub >  = 30 min), and 30 %..." /> Based on the results of this study, we suggest that for BCS class III drug with high < em class= " a-plus-plus " > F < /em > < sub class= " a-plus-plus " > a < /sub > (about & gt;80  %), the biowaiver should extend to rapid dissolution ( < em class= " a-plus-plus " > T < /em > < sub class= " a-plus-plus " > 85  % < /sub >  = 30 min), and 30 %..." />

Exploring the Feasibility of Biowaiver Extension of BCS Class III Drugs with Site-Specific Absorption Using Gastrointestinal Simulation Technology

Conclusions < /h3 > < p class= " a-plus-plus " > Based on the results of this study, we suggest that for BCS class III drug with high < em class= " a-plus-plus " > F < /em > < sub class= " a-plus-plus " > a < /sub > (about & gt;80  %), the biowaiver should extend to rapid dissolution ( < em class= " a-plus-plus " > T < /em > < sub class= " a-plus-plus " > 85  % < /sub >  = 30 min), and 30 % of < em class= " a-plus-plus " > F < /em > < sub class= " a-plus-plus " > a < /sub > as the boundary of intermediate permeability class (30  %  & lt;   < em class= " a-plus-plus " > F < /em > < sub class= " a-plus-plus " > a < /sub >   & lt;  85 %). < /p > < /span >
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research